A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis

Abstract

Background: Osteoarthritis (OA) is progressive degenerative damage to articular cartilage. Current therapeutic options are reduced to control the OA-associated symptoms, leaving the degenerative changes to progress until a joint replacement becomes mandatory. Therefore, therapeutic alternatives are warranted to improve the patient's quality of life. Cell-based therapy is a developing therapeutic modality, showing promising results in the regeneration of injured cartilage and reduction of on-going inflammation within the affected joint. The current retrospective chart review study was aimed to analyze changes in pain and mobility of subjects with OA after stromal vascular fraction (SVF) cell therapy.Methods: Three hundred fifty subjects with hip and knee OA, treated with autologous SVF cells at the Malacky Hospital (Bratislava, Slovakia) in the period from 2015 to 2018, were included in the retrospective chart review study.Results: Seven days after SVF cell therapy, 45.2% of subjects experienced improved pain levels and mobility. Three, 6, and 12 months after therapy, improvement in pain levels reached 75.3%, 84.4%, and 84.9%, and improvement in mobility reached 75.2%, 84.4%, and 84.9%. Conclusions:Our study of 350 subjects with hip and knee OA showed a significant improvement in pain levels and mobility 3, 6, and 12 months compared to 7 days after autologous SVF cell administration. The treatment demonstrated a strong safety profile with no severe adverse events or complications reported. The results of the study are showing that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV.

Analyzing the Clinical Potential of Stromal Vascular Fraction: A Comprehensive Literature Review

“…After removing duplicates and screening titles and abstracts, 84 full-text articles were assessed for eligibility. Of these, 16 articles met the inclusion criteria and were included in the review (Table 1) [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. The selected studies included prospective and/or retrospective case series, randomized controlled clinical trials, and reviews.…”

Clinical use of autologous adipose-derived stromal vascular fraction cell injections for hip osteoarthritis

“…SVF treatment of knee OA is being established as a safe and effective method; however, only a few studies showing the efficacy of SVF treatment for hip OA have been published. One previous study involved only six patients [ 34 ], and another was a large clinical trial that did not include a detailed clinical evaluation [ 35 ]. However, during this study, a prospective, varied, and detailed clinical evaluation was conducted using a sufficient sample size.…”

Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) for Knee Osteoarthritis

“…A follow-up procedure for patients with an FDA-approved device was defined [ 111 ]. Pain decreased and function improved when SVF was administered together with PRP in 350 knee and hip OA patients [ 112 ]. A total of 80 male and 65 female patients between the ages of 15 and 85 received SVF after collagenase digestion [ 62 ].…”